CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Raloxifene

雷洛昔芬 杂质对照品Raloxifene Impurities

EP39 个杂质条目39 impurity entries

本页汇总 雷洛昔芬 的 39 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 39 impurity reference standards of Raloxifene with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 雷洛昔芬(Raloxifene)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesAdvancement in optimization tactic achieved by newly developed chromatographic response function: application to LC separation of raloxifene and its impurities
    Talanta · 2011 · Jančić-Stojanović B et al.  ·  PMID 21807209  ·  DOI
  2. 杂质研究Impurity studiesSystematical approach in evaluation of LC method for determination of raloxifene hydrochloride and its impurities employing experimental design
    Journal of pharmaceutical analysis · 2013 · Jančić Stojanović B et al.  ·  PMID 29403795  ·  DOI
  3. 杂质研究Impurity studiesInfluence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product
    Pharmaceutical development and technology · 2000 · Hartauer KJ et al.  ·  PMID 10934729  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of ultra-high-performance liquid chromatography-mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: Application to pharmacokinetic studies in rats
    Journal of separation science · 2020 · Du T et al.  ·  PMID 33119204  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisRecent advances in the synthesis of raloxifene: a selective estrogen receptor modulator
    European journal of medicinal chemistry · 2012 · Dadiboyena S  ·  PMID 22405286  ·  DOI

雷洛昔芬 —— 原料药与杂质对照品Raloxifene — drug substance & impurities

共 39 个条目(含原料药本体)39 items incl. the drug substance
Raloxifene Impurity 1(Raloxifene EP Impurity A) structure
EPA
雷洛昔芬杂质1(雷洛昔芬EP杂质A)Raloxifene Impurity 1(Raloxifene EP Impurity A)
Raloxifene Impurity 1(Raloxifene EP Impurity A)
CAS No.1159977-58-8
Chemical FormulaC42H44N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 2(Raloxifene EP Impurity B) structure
EPB
雷洛昔芬杂质2(雷洛昔芬EP杂质B)Raloxifene Impurity 2(Raloxifene EP Impurity B)
Raloxifene Impurity 2(Raloxifene EP Impurity B)
CAS No.1391054-73-1
Chemical FormulaC28H27NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 3(Raloxifene EP Impurity C) structure
EPC
雷洛昔芬杂质3(雷洛昔芬EP杂质C)Raloxifene Impurity 3(Raloxifene EP Impurity C)
Raloxifene Impurity 3(Raloxifene EP Impurity C)
CAS No.195454-31-0
Chemical FormulaC28H27NO5S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 4(Raloxifene EP Impurity D) structure
EPD
雷洛昔芬杂质4(雷洛昔芬EP杂质D)Raloxifene Impurity 4(Raloxifene EP Impurity D)
Raloxifene Impurity 4(Raloxifene EP Impurity D)
CAS No.177744-96-6
Chemical FormulaC21H14O4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 5 structure
5
雷洛昔芬杂质5Raloxifene Impurity 5
Raloxifene Impurity 5
CAS No.84449-80-9
Chemical FormulaC14H20ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 6 structure
6
雷洛昔芬杂质6Raloxifene Impurity 6
Raloxifene Impurity 6
CAS No.2008-75-5
Chemical FormulaC7H14ClNHCl
Purity>95%现货In stock
10mg25mg50mg100mg
Raloxifene Impurity 7 structure
7
雷洛昔芬杂质7Raloxifene Impurity 7
Raloxifene Impurity 7
CAS No.84449-65-0
Chemical FormulaC16H14O6S3
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 8 structure
8
雷洛昔芬杂质8Raloxifene Impurity 8
Raloxifene Impurity 8
CAS No.63676-22-2
Chemical FormulaC14H10O2S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 9 structure
9
雷洛昔芬杂质9Raloxifene Impurity 9
Raloxifene Impurity 9
CAS No.1026927-78-5
Chemical FormulaC30H31NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 10 structure
10
雷洛昔芬杂质10Raloxifene Impurity 10
Raloxifene Impurity 10
CAS No.618902-12-8
Chemical FormulaC56H52N2O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 11 structure
11
雷洛昔芬杂质11Raloxifene Impurity 11
Raloxifene Impurity 11
CAS No.182249-24-7
Chemical FormulaC40H55NO4SSi2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 12 structure
12
雷洛昔芬杂质12Raloxifene Impurity 12
Raloxifene Impurity 12
CAS No.185415-07-0
Chemical FormulaC29H29NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 13 structure
13
雷洛昔芬杂质13Raloxifene Impurity 13
Raloxifene Impurity 13
CAS No.178451-13-3
Chemical FormulaC29H29NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 14 structure
14
雷洛昔芬杂质14Raloxifene Impurity 14
Raloxifene Impurity 14
CAS No.185416-01-7
Chemical FormulaC28H27NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 15 structure
15
雷洛昔芬杂质15Raloxifene Impurity 15
Raloxifene Impurity 15
CAS No.174264-47-2
Chemical FormulaC34H41NO4SSi
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 16 structure
16
雷洛昔芬杂质16Raloxifene Impurity 16
Raloxifene Impurity 16
CAS No.174264-46-1
Chemical FormulaC34H41NO4SSi
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 17 structure
17
雷洛昔芬杂质17Raloxifene Impurity 17
Raloxifene Impurity 17
CAS No.84541-38-8
Chemical FormulaC30H31NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 18 structure
18
雷洛昔芬杂质18Raloxifene Impurity 18
Raloxifene Impurity 18
CAS No.84449-85-4
Chemical FormulaC30H31NO8S3·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 19 structure
19
雷洛昔芬杂质19Raloxifene Impurity 19
Raloxifene Impurity 19
CAS No.334758-18-8
Chemical FormulaC34H37NO9S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 20 structure
20
雷洛昔芬杂质20Raloxifene Impurity 20
Raloxifene Impurity 20
CAS No.334758-19-9
Chemical FormulaC34H37NO9S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 21 structure
21
雷洛昔芬杂质21Raloxifene Impurity 21
Raloxifene Impurity 21
CAS No.182507-20-6
Chemical FormulaC40H43NO16S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 22 structure
22
雷洛昔芬杂质22Raloxifene Impurity 22
Raloxifene Impurity 22
CAS No.174264-51-8
Chemical FormulaC41H43NO13S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 23 structure
23
雷洛昔芬杂质23Raloxifene Impurity 23
Raloxifene Impurity 23
CAS No.174264-50-7
Chemical FormulaC34H35NO10S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 24 structure
24
雷洛昔芬杂质24Raloxifene Impurity 24
Raloxifene Impurity 24
CAS No.182507-22-8
Chemical FormulaC34H35NO10S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 25 structure
25
雷洛昔芬杂质25Raloxifene Impurity 25
Raloxifene Impurity 25
CAS No.63675-74-1
Chemical FormulaC16H14O2S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 26 structure
26
雷洛昔芬杂质26Raloxifene Impurity 26
Raloxifene Impurity 26
CAS No.3040-44-6
Chemical FormulaC7H15NO
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 27 structure
27
雷洛昔芬杂质27Raloxifene Impurity 27
Raloxifene Impurity 27
CAS No.91444-47-2
Chemical FormulaC14H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 28 structure
28
雷洛昔芬杂质28Raloxifene Impurity 28
Raloxifene Impurity 28
CAS No.86111-03-7
Chemical FormulaC15H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 29 structure
29
雷洛昔芬杂质29Raloxifene Impurity 29
Raloxifene Impurity 29
CAS No.62613-53-0
Chemical FormulaC15H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 30 structure
30
雷洛昔芬杂质30Raloxifene Impurity 30
Raloxifene Impurity 30
CAS No.62655-56-5
Chemical FormulaC16H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 31 structure
31
雷洛昔芬杂质31Raloxifene Impurity 31
Raloxifene Impurity 31
CAS No.225648-21-5
Chemical FormulaC15H12O2S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 32 structure
32
雷洛昔芬杂质32Raloxifene Impurity 32
Raloxifene Impurity 32
CAS No.175460-94-3
Chemical FormulaC15H12O2S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 33 structure
33
雷洛昔芬杂质33Raloxifene Impurity 33
Raloxifene Impurity 33
CAS No.3235-67-4
Chemical FormulaC7H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 34 structure
34
雷洛昔芬杂质34Raloxifene Impurity 34
Raloxifene Impurity 34
CAS No.182133-38-6
Chemical FormulaC15H12O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 35 structure
35
雷洛昔芬杂质35Raloxifene Impurity 35
Raloxifene Impurity 35
CAS No.63762-93-6
Chemical FormulaC15H14O3S
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 37 structure
37
雷洛昔芬杂质37Raloxifene Impurity 37
Raloxifene Impurity 37
CAS No.14446-67-4
Chemical FormulaC8H15N
Purity>95%询价On request
10mg25mg50mg100mg
Raloxifene Impurity 15-d4 structure
15-D4
雷洛昔芬杂质15-d4Raloxifene Impurity 15-d4
Raloxifene Impurity 15-d4
CAS No.1329611-25-7
Chemical FormulaC34H37D4NO4SSi
Purity>95%询价On request
Raloxifene Impurity 16-d4 structure
16-D4
雷洛昔芬杂质16-d4Raloxifene Impurity 16-d4
Raloxifene Impurity 16-d4
CAS No.1189422-34-1
Chemical FormulaC34H37D4NO4SSi
Purity>95%询价On request
Raloxifene Impurity 17-d4 structure
17-D4
雷洛昔芬杂质17-d4Raloxifene Impurity 17-d4
Raloxifene Impurity 17-d4
CAS No.1185006-58-9
Chemical FormulaC30H27D4NO4S
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

雷洛昔芬 —— 研究文献与合成路线Raloxifene — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 雷洛昔芬 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Raloxifene. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product
    Hartauer KJ, Arbuthnot GN, Baertschi SW, et al. · Pharmaceutical development and technology · 2000 · 被引 63cited 63
  2. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques
    Smith LJ, Henderson JA, Abell CW, et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2004 · 被引 120cited 120
  3. Rational Design of Methylene Blue-Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation
    Zhang Y, Yu Q, Wang Z, et al. · Journal of medicinal chemistry · 2025 · 被引 5cited 5
  4. Advancement in optimization tactic achieved by newly developed chromatographic response function: application to LC separation of raloxifene and its impurities
    Jančić-Stojanović B, Rakić T, Kostić N, et al. · Talanta · 2011 · 被引 7cited 7
  5. Rational design, synthesis, and biological evaluation of Raloxifene-based potent degrader of estrogen receptor alpha
    Tian Y, Sun Y, Han K, et al. · Bioorganic chemistry · 2025
  6. Systematical approach in evaluation of LC method for determination of raloxifene hydrochloride and its impurities employing experimental design
    Jančić Stojanović B, Rakić T, Slavković B, et al. · Journal of pharmaceutical analysis · 2013 · 被引 2cited 2

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF RALOXIFENE HYDROCHLORIDE
    PARTHASARADHI REDDY BANDI, RATHNAKAR REDDY KURA, MURALIDHARA REDDY DASARI, RAJI REDDY RAPOLU, et al. · 公开号 WO2011132194WO2011132194 · 2011
  2. PREPARATION OF RALOXIFENE AND ITS SALTS
    SANDEEP MOHANTY, GADDAMEEDHI PRASHANTH REDDY, MOHAN GUNTI MURALI, REDDY KESAVA, et al. · 公开号 WO2011029088WO2011029088 · 2011
  3. NEW ADDITION SALTS OF RALOXIFENE, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN THERAPY
    RUCMAN RUDOLF, ZUPET PAVEL, SUNIL DOSHI · 公开号 WO2011099942WO2011099942 · 2011
  4. PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE
    — · 公开号 IL172801IL172801 · 2011
  5. PROCEDURE FOR PREPARATION OF NEW ADDITION SALTS OF RALOXIFENE AND THEIR USE IN THERAPY
    RUCMAN RUDOLF, ZUPET PAVEL, SUNIK K DOSHI · 公开号 SI23391SI23391 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

雷洛昔芬 杂质谱研究要点Raloxifene — impurity profiling notes

下面这些是拿到 雷洛昔芬 的 39 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 39 impurity entries for Raloxifene, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances